to relax (lusitropy); and therefore, targeting cMyBP-C phosphorylation has the potential for translation to a novel therapy for HFpEF.
cMyBP-C is a thick filament accessory protein that binds at 42-nm intervals within the C-zone of the A-band of the sarcomere. 5, 6 cMyBP-C is readily phosphorylated by a host of kinases, such as protein kinase A (PKA), 7 PKC, 8 PKD, 9 calcium calmodulin kinase IIδ (CAMK2δ), 10 glycogen synthase kinase 3β, 11 and ribosomal S6 kinase. 12 Unphosphorylated cMyBP-C seems to repress both cross-bridge attachment and detachment. [13] [14] [15] [16] On phosphorylation, cMyBP-C releases its inhibitory effects to accelerate the rate of cross-bridge cycling 14 to suggest that cMyBP-C phosphorylation may play an important role in mediating lusitropy. Furthermore, review of human HF and animal models also suggest that cMyBP-C may mediate diastolic function. 17 However, the possibility that phosphorylation of cMyBP-C directly enhances whole-heart lusitropy has not been established.
We hypothesized that phosphorylation of cMyBP-C enhances lusitropy. To test this idea, we created a cMyBP-C phosphomimetic cMyBP-C(t3SD) mouse and used existing mouse models expressing phosphorylatable wild-type (WT) cMyBP-C or phosphorylation-deficient mutant cMyBP-C(t3SA) to assess the effects of phosphorylation status on diastolic function. Our studies showed that phosphorylation of cMyBP-C enhanced lusitropy, whereas the absence of phosphorylation at the 3 PKA sites in the M-domain of cMyBP-C depressed lusitropy and gave rise to phenotypes associated with HFpEF.
Methods

Mouse Lines
All protocols for animal care and use were approved by the Institutional Animal Care and Use Committees at the Texas A&M University Health Science Center College of Medicine Temple campus and the University of Wisconsin School of Medicine and Public Health. Aspartic-acid for serine substitutions were made at the 3 known PKA sites (S273D, S282D, and S302D) in the M-domain of cMyBP-C to mimic the negative charge of phosphorylation ( Figure 1A ). An N-terminal cMyc-tag was included for identification, and the α-myosin heavy chain promoter was used to target expression to the heart. The t3SD transgene was expressed transgenically on the cMyBP-C(−/−) null background 18 to generate the cMyBP-C(t3SD) mouse. The WT control cMyBP-C(tWT) mouse and the phosphorylation-deficient cMyBP-C(t3SA) mouse were described previously. 14 The protein expression levels of cMyBP-C in comparison with true WT were cMyBP-C(tWT), 72%; cMyBP-C(t3SA), 74%; and cMyBP-C(t3SD), 84%. We used mice at 3 months±2 weeks of age at a ratio of ≈1:1 female to male, unless otherwise specified.
Immunofluorescence
Immunofluorescent labeling of myofibrils was used to verify incorporation of transgenic cMyBP-C(t3SD) protein into sarcomeres, using a protocol modified from a previous study. 14 Rabbit polyclonal anti-cMyBP-C antibody 18 at 1:250 dilution was paired with Alexa-Fluor488® (Life Technologies) goat anti-rabbit secondary antibody at 1:250 dilution. Mouse monoclonal anti-cMyc (Clone 9E10, EMD Millipore) at 1:25 dilution was paired with Alexa-Fluor543® (Life Technologies) goat anti-mouse secondary antibody at 1:250 dilution. Goat polyclonal anti-α-actinin (Santa Cruz Biotechnology) at 1:25 dilution was paired with Alexa-Fluor647® (Life Technologies) donkey anti-goat secondary antibody at 1:250 dilution. A Leica SP2 confocal microscope with ×63 oil immersion objective was used for imaging. Lasers with wavelengths of 488 nm, 543 nm, and 633 nm were used to excite the fluorescent secondary antibodies to image cMyBP-C, cMyc (transgenic protein tag), and α-actinin (Z-disc).
Two-Dimensional Differential In-Gel Electrophoresis
Two-dimensional differential in-gel electrophoresis (2D-DIGE) was used to determine the isoelectric migration patterns of contractile proteins from all lines (tWT, t3SA, and t3SD) using a protocol described previously. 19, 20 Cardiac myofibrils were prepared from left ventricular (LV) tissue and resuspended in UTC buffer (8 mol/L urea, 2 mol/L thiourea, and 4% CHAPS). An RC-DC assay (Bio-Rad) was performed to determine protein concentrations in each of the samples. After 2D clean up (GE Healthcare 2D Clean-Up Kit), a total of 100 μg of protein was labeled with 100 pmol of Cy2, Cy3, or Cy5 (GE Healthcare)/50 μg protein, according to methods described previously. 21, 22 The internal control was prepared by labeling each sample equally with Cy2 to facilitate gel-to-gel comparisons. Equal amounts of Cy2, Cy3, and Cy5-labeled protein were loaded onto either 24 cm (pH, 3-11) or 18 cm (pH, 4-7) or 18 cm (pH, 7-11) immobilized pH gradient strips (GE Healthcare) and focused in a Bio-Rad Protean IEF cell. To separate cMyBP-C spots, 24 cm, pH 3 to 11 strips were used. 23 The focused pH 4 to 7 and pH 7 to 11 strips were used to separate myosin light chain 2 21 and cardiac troponin I (cTnI) 24 spots, respectively. Focused immobilized pH gradient strips were then subjected to electrophoresis in 12% SDS polyacrylamide gels. 25 Gels were imaged with a Typhoon 9410 Imager (GE Healthcare). Images were analyzed using PDQuest 8.0 Advanced software (Bio-Rad).
Measurement of Physiological Parameters
Voluntary running was used to compare overall physiological effect of cMyBP-C phosphorylation status. Mice at 6 weeks of age were singly housed with a low profile running wheel (Med-Associates ENV-044-01, DIG-804) for 6 weeks. A wireless hub continuously recorded the number of revolutions from all running wheels with 30-second time resolution. Running wheels were checked for malfunction twice per week.
Animals were euthanized, and heart weight/body weight and lung weight/body weight ratios were measured as indicators of cardiac hypertrophy and pulmonary edema, respectively.
Brain natriuretic peptide (BNP) mRNA levels were measured in myocardial samples as a biochemical indicator of HF. We quantified BNP mRNA levels in hearts of all 3 lines of mice. Mice were anesthetized using 4% inhaled isoflurane, and hearts were quickly removed and frozen rapidly in liquid nitrogen. Total RNA was isolated using TRIzol Reagent (Life Technologies), and first strand cDNA was synthesized using the RT2 First Strand kit (QIAGEN). Real-time polymerase chain reaction was performed using an Agilent Mx3005P qPCR system (Agilent Technologies) with RT2 SYBR Green ROX qPCR Master Mix (QIAGEN). Cycle threshold value was obtained to calculate the relative expression levels of BNP and GAPDH (used as internal control) in each sample using Mx Pro QPCR software (Agilent Technologies). The gene-specific primers for amplifying BNP (primer PPM04558A) and GAPDH (primer PPM02946E) were obtained from QIAGEN.
Echocardiography
A VisualSonics Vevo 2100 system (FUJIFILM VisualSonics Inc) with a probe providing 30-μm spatial resolution was used to assess in vivo cardiac structure and function. Unlike the older Vevo 770 system, the Vevo 2100 system has time resolution that allows imaging of the beating mouse heart in real time. Real-time measurements with the Vevo 2100 produce absolute measurement values that differ from the older Vevo 770, which relied on ECG gating to guide reconstruction of heart from slices that were imaged at different points in time. The t3SA mutation introduces Ala for Ser substitutions at the same 3 PKA sites, whereas the t3SD mutation introduces Asp for Ser substitutions at the same sites. All transgenic proteins were engineered to contain an N-terminal cMyc-tag. B, Green indicates anti-cMyBP-C, red indicates anti-cMyc, blue shows anti-α-actinin, and yellow results from merging of anti-cMyBP-C and anti-cMyc. I-IV, Wild-type (WT) myofibrils with green doublets that correspond to endogenous cMyBP-C (I and III) and blue lines (IV) corresponding to α-actinin located at the Z-discs. Thus, cMyBP-C seems as green doublets within the sarcomeres, which in turn are delineated by blue at the Z-discs. V-VIII, cMyBP-C(−/−) myofibrils with only blue lines (VIII) corresponding to α-actinin binding at the Z-discs. IX-XII, cMyBP-C(t3SD) myofibrils with green doublets (IX) indicating cMyBP-C and red doublets (X) indicating c-Myc-labeled transgenic proteins in the same labeling pattern. Yellow (XI) signifies that the cMyBP-C and cMyc doublets overlap, showing that our transgenic protein is appropriately positioned in the sarcomere. XII, Green doublets corresponding to cMyBP-C lay between the blue α-actinin bands located in the Z-discs. C, WT myofibril image section was enlarged to show a single sarcomere delineated by Z-discs and cMyBP-C appearing as green doublets that are localized to the C-zone of the A-band and the empty H-zone in the middle. Because of the inability of our ×63 (Continued) Therefore, absolute numbers from this study are not directly comparable with those from previous studies. 14 Mice were anesthetized with 0.5% to 2% isoflurane, the ECG was monitored continuously in real time, and isoflurane was adjusted to keep the heart rate at 380 to 440 beats per minute. The echo-table temperature was controlled at 39°C. 2D imaging, blood flow Doppler, tissue Doppler, and M-mode measurements were done. All mice recovered from the procedure without signs of distress.
Pressure-Volume Measurements
Intraventricular pressure and volume were measured with 1.2F Scisense pressure-volume admittance catheters (Transonic Systems Inc). Anesthesia was induced with 4% isoflurane, which was reduced to 1% after a surgical plane of anesthesia was achieved. Through a midline cervical incision, the right carotid artery was identified, isolated, and then cannulated to insert the 1.2F pressure-volume loop catheter. Left ventricular pressure and volume were recorded using the iWorx IX/228S Data Acquisition System (Transonic Systems Inc) with a Scisense Advantage pressure-volume control unit version 5.0. Left ventricular stiffness is calculated by P(v)=Ae (v×stiffness) +P offset , where P(v) is the end-diastolic pressure and v is the end-diastolic volume. A is a curve fitting constant 26 corresponding to the slow gentle rise portion of the curve. Stiffness is the stiffness constant 26 of the ventricle corresponding to the approximately exponential-rise portion of the curve. Pressure offset is calculated (P offset ) to quantify a shift in the position of the end-diastolic pressure-volume relationship with or without an accompanying change in the steepness of the relationship, which also includes an instrumentation offset.
Force/Calcium Measurements on Intact Papillary Muscle
Simultaneous intracellular calcium [Ca 2+ ] i and force measurements were performed on intact papillary muscles to determine whether variations in Ca 2+ reuptake accounted for possible differences in relaxation among the 3 mouse models. We modified a previous protocol 27 for this purpose. Right ventricular papillary muscles were carefully isolated and mounted onto the apparatus. Force transducer (Aurora Scientific) measured the force. Hyperswitch system (IonOptix LLC) measured intracellular Fura-2 AM (TEFLabs) fluorescence as the indicator of [Ca 2+ ] i . Pacing frequency was increased (1-2.5 Hz) to simulate the increasing heart rate. Papillary muscles were continuously superfused at room temperature to avoid the rapid extrusion of Fura-2 AM that occurs at higher temperatures. 27 Recordings of fluorescence at 510 nm from calcium-bound Fura-2 AM (F Ca ; 340-nm excitation) and calcium-free Fura-2 AM (F free ; 380-nm excitation) were obtained.
[Ca 2+ ] i was estimated based on the F Ca /F free ratio after correcting for background and sequestered Ca 2+ . Measurements were obtained at the length that yielded maximum twitch force for each muscle. Trains of >30 contractions were averaged to produce traces that were subsequently used for data analysis.
Interpretation of Key Measurements
Echocardiographic tissue Doppler measurements of peak myocardial relaxation velocity in early diastole (E a ) correspond to the peak rate of pressure decay (−dP/dt) min . 28 Similarly, tissue Doppler of peak myocardial contraction velocity in systole (S a ) corresponds to the peak rate of pressure increase (+dP/dt) max . 29 Because pressure is a function of force, (-dF/dt) min and (+dF/dt) max in intact papillary muscles would correspond to intraventricular (−dP/dt) min and (+dP/dt) max , respectively. These relationships then allow one to relate intact papillary function to intact in vivo cardiac function by [dFR=(-dF/dt) min /(+dF/dt) max ]≈dPR=(−dP/dt) min /(+dP/dt) max ]≈E a /S a . Increased E/E a is a reliable echocardiographic indicator of diastolic dysfunction because it captures both increasing left atrial pressure (ie, increasing pressure will increase blood inflow velocity E across the mitral valve) and the decreased ability of the myocardium to relax (ie, decreased E a ). 3,30-32 τ-Glantz is a pressure decay time constant obtained from intracardiac pressure measurements, with a smaller number indicating faster relaxation. 33 dFR normalizes peak relaxation to peak contraction to allow the comparison of intrinsic lusitropy of papillary muscles across different geometries and different peak rates of force development. Furthermore, increases in dFR indicate acceleration of relaxation because increases in the peak rate of relaxation must exceed the peak rate of force development for this to occur.
Statistical Analysis
Statistical analyses were done with a combination of SPSS and R statistical analysis software with significance set at P<0.05. Combination of a normal appearing histogram and non-significant Shapiro-Wilkes test qualified a data set as being normal. Normally distributed data sets were analyzed with an ANOVA post hoc Tukey test because there were at least 3 groups in each comparison. Repeated measurements, such as responses to increased pacing frequency within the same group, were tested with repeated measures ANOVA.
Data sets that did not qualify as normal were analyzed using exact tests. For groups >2, the Kruskal-Wallis test was used to show the presence of a group with a significantly different distribution from the others. Afterward, a Mann-Whitney U-test with the Holm-Bonferroni adjustment for multiple comparisons was used to identify which group(s) differed from the others. For repeated measurements within the same group, Friedman 2-way ANOVA by rank was used to detect differences in distributions. For all analyses, the use of either a parametric test or an exact test did not affect the conclusions.
Whenever possible, box plots were used to display the data with the values of the box bottom at the 25th percentile, the median line within the box, and the box top at the 75th percentile; the bottom whisker at the 10th percentile and the top whisker at the 90th percentile.
Results
Immunofluorescence and 2D-DIGE experiments showed that phosphorylation mimetic cMyBP-C(t3SD) protein was properly incorporated and electrically charged and had no effect on the post-translational modification of other myofilament proteins.
Immunofluorescent triple labeling of cMyBP-C, α-actinin (Z-disk), and cMyc (transgenic protein label) demonstrated that cMyBP-C(t3SD) protein was appropriately incorporated and properly positioned within the myofibril ( Figure 1B and 1C) . The proper incorporation of cMyBP-C(t3SA) protein was verified in a previous study. 14 The t3SD mutations, which caused Figure 1 Continued. oil objective to resolve the cMyBP-C transverse bands that are separated by intervals of 42 nm along the thick filaments, the cMyBP-C bands 6 on either side of H-zone sarcomere seem as a green doublet. Correct incorporation of phosphorylationdeficient cMyBP-C t3SA protein has been demonstrated in a previous publication. 14 D, 2-dimensional differential gel electrophoresis. + is the positive terminal to which more negative (ie, acidic isoelectric point with low pI) proteins migrate. − is the negative terminal toward which more positive proteins travel. I-III: cMyBP-C(tWT) is labeled with Cy5-red (I) along with 7 spots that were quantified. cMyBP-C(t3SD) is labeled with Cy3-green (II). The merged images (III) show that cMyBP-C(t3SD) spots migrated to more negative pI, consistent with the introduction of Ser to Asp mutations. IV-VI: cMyBP-C(tWT) is labeled with Cy3-green (IV) and cMyBP-C(t3SA) is labeled with Cy5-red (V). The cMyBP-C(t3SA) spots migrated to a more neutral pI with respect to cMyBP-C(tWT), as demonstrated in the merged image (VI). VII-IX: cMyBP-C(t3SD) is labeled with Cy3-green, whereas cMyBP-C(t3SA) is labeled with Cy5-red. The merged image showed that cMyBP-C(t3SD) spots had a much more negative distribution, ie, there was little overlap with cMyBP-C(t3SA) spots. The accompanying bar graph shows the quantified intensities of each spot in hearts from the 3 mouse models.
cMyBP-C to be more negatively charged, redistributed the 2D-DIGE cMyBP-C spots to more acidic regions (ie, nearer the positive pole, Figure 1D ). The t3SA mutations, which caused the protein to be more neutrally charged, redistributed the 2D-DIGE cMyBP-C spots to more neutral regions (ie, nearer the center; Figure 1D ). 2D-DIGE analyses showed similar distributions of spots for cTnI, cardiac troponin-T4, cardiac tropomyosin, and myosin light chain-2 for all 3 mouse lines (Figures I and II in the Data Supplement); therefore, the cMyBP-C mutations did not change the post-translational modification of these proteins. Furthermore, all 3 mouse lines exhibited similar levels of titin phosphorylation ( Figure III in the Data Supplement).
Phosphorylation-Deficient cMyBP-C(t3SA) Mouse, but Not the Phosphomimetic cMyBP-C(t3SD) Mouse, Showed Signs of HF
After an acclimatization period of 4 weeks, we found that cMyBP-C(tWT) and cMyBP-C(t3SD) mice ran voluntarily ≤≈12 km/d (Figure 2A ). cMyBP-C(t3SA) mice exhibited shorter running distances of ≈5 km/d (Figure 2A ). The shorter running distances for cMyBP-C (t3SA) mice suggest that lack of cMyBP-C phosphorylation leads to a loss of cardiac reserve, which is often seen in HF. Similar running distances among cMyBP-C(tWT) and cMyBP-C(t3SD) mice suggest that constitutively phosphorylated cMyBP-C either have normal cardiac reserve or cardiac function was sufficiently high at baseline that running did not exceed the capability of the heart to deliver adequate blood flow. cMyBP-C(t3SA) mice had increased heart weight/body weight ratios ( Figure 2B) , an indicator of cardiac hypertrophy, and increased lung weight/body weight ratio, an indicator of pulmonary edema, suggesting the presence of HF ( Figure 2C ). cMyBP-C(t3SD) mice showed heart weight/body weight and lung weight/body weight ratios similar to MyBPC(tWT) mice ( Figure 2B and  2C) , indicating that the phosphomimetic cMyBP-C(t3SD) mouse does not exhibit HF. cMyBP-C(t3SD) mice showed similar levels of BNP when compared with MyBPC(tWT) controls ( Figure 2D ). In contrast, BNP levels were elevated in cMyBP-C(t3SA) mice ( Figure 2D ). In summary, shorter running distances, increased heart/body weight ratio, presence of pulmonary edema, and elevated BNP combined to strongly suggest that cMyBP-C(t3SA) mice exhibit HF.
Echocardiography Showed That cMyBP-C Phosphorylation Is a Significant Determinant of Diastolic Function
Echocardiography was performed on mice at an average age of 3 to 4 months to quantify in vivo function, which was done at similar heart rates in all 3 lines. All 3 mouse lines exhibited LV ejection fraction (LVEF) of >50% (Figure 3 ). cMyBP-C(t3SA) hearts showed prominently increased LV posterior wall thickness, mildly decreased LVEF that was still >50%, and mildly increased LV internal diameter during diastole (Figure 3) .
cMyBP-C(t3SA) hearts exhibited depressed lusitropy evidenced by slower peak myocardial relaxation velocity (E a ) at the mitral valve annulus ( Figure 3B and 3H ; Videos in the Data Supplement) and increased isovolumetric relaxation time ( Figure 3F ), indicating impaired relaxation. Conversely, cMyBP-C(t3SD) hearts showed markedly faster E a . Because faster E a corresponds to faster peak rates of LV pressure decay (−dP/dt) min and a shorter pressure decay time constant during diastole, 28 we conclude that cMyBP-C(t3SD) hearts exhibited enhanced lusitropy when compared with cMyBP-C(t3SA) and cMyBP-C(tWT) models ( Figure 3B and 3H ; Videos in the Data Supplement). The ratio of peak blood inflow velocity across the mitral valve during early diastole (E) to peak myocardial relaxation velocity (E a ) at the mitral valve annulus (E/E a ) was used to evaluate diastolic dysfunction. 4, 28, 31, 32 The E/E a ratios in cMyBP-C(t3SA) hearts Nonphosphorylatable cMyBP-C(t3SA) mouse exhibited signs of heart failure. A, Singly caged mice voluntarily ran on wheels that continuously logged rotations via a wireless hub. The cMyBP-C(t3SA) mice ran shorter distances. cMyBP-C(tWT) and cMyBP-C(t3SD) mice ran longer and similar distances. All mouse lines demonstrated increasing running distances vs week 1 using Friedman analysis of variance by rank with Holm-Bonferroni adjustment for multiple comparisons; however, cMyBP-C(t3SA) mice took longer to increase running distances. cMyBP-C(tWT) and cMyBP-C(t3D) running distances showed positive correlation with weeks by Spearman correlation. B, cMyBP-C(t3SA) mice exhibited increased heart weight/body weight (HW/BW) ratios suggesting the presence of hypertrophy. C, cMyBP-C(t3SA) mice had increased lung weight/body weight (LW/BW) ratios suggesting pulmonary edema. D, Brain natriuretic peptide (BNP) mRNA levels were used as a marker for heart failure. cMyBP-C(t3SA) mice exhibited significantly increased levels of BNP. cMyBP indicates cardiac myosinbinding protein-C.
were significantly higher than in cMyBP-C(tWT) hearts, which is evidence of diastolic dysfunction. 4, [30] [31] [32] In contrast, cMyBP-C(t3SD) hearts exhibited decreased E/E a ratios, demonstrating enhanced diastolic function ( Figure 3J ). The ratio of peak relaxation/peak contraction velocities (E a /S a ) was used as another measure of diastolic dysfunction as these variables correspond to the rates of pressure change (−dP/dt) min 28 and (+dP/dt) max , 29 respectively. cMyBP-C(t3SD) hearts showed the highest E a /S a ratio, and cMyBP-C(t3SA) hearts showed the lowest E a /S a ratio when all models are compared ( Figure 3I ), further confirming enhanced diastolic function in the cMyBP-C(t3SD) mouse and depressed diastolic dysfunction in the cMyBP-C(t3SA) mouse. Thus, the cMyBP-C(t3SD) mouse consistently demonstrated enhanced diastolic function, whereas cardiac function in cMyBP-C(t3SA) mice resembled HFpEF. Additional echocardiography examinations were performed on mice at an average age of 12 to 13 months at similar heart rates to document possible effects of age on the results. Unlike the results at 3 to 4 months of age, all lines showed similar LV internal diameter during diastole and similar LVEF. In comparison with other 2 lines, the cMyBP-C(t3SA) hearts from older mice exhibited thickened LV walls, slower myocardial relaxation velocity in early diastole (E a ), and the smallest E a /S a ratio to indicate diastolic dysfunction. The cMyBP-C(t3SD) hearts showed the fastest E a and the smallest E/E a ratio to indicate enhanced diastolic function. However, cMyBP-C(t3SD) now exhibits the fastest S a . Older cMyBP-C(t3SA) hearts showing similar LV internal diameter during diastole and LVEF as other lines reinforced the notion that cardiac function with phosphorylation-deficient cMyBP-C resembles HFpEF. Furthermore, the cMyBP-C(t3SD) results demonstrated that cMyBP-C phosphorylation-dependent enhancement of diastolic function is preserved with aging (details are available in Figure  IV in the Data Supplement).
Systolic Blood Pressure Measurements Are Similar Between Mouse Lines
Systolic blood pressures were measured by tail cuffs on restrained conscious mice at similar ages of 75 to 82 days. All lines exhibited similar peak systolic blood pressures. The values in millimeter of mercury were 103.0±2.5 (cMyBPC(tWT); n=5), 108.8±2.3 (cMyBP-C(t3SA); n=6), and 102.6±2.5 (cMyBP-C(t3SD); n=5). . Pressure-volume measurements. Intracardiac pressure and volume measurements were performed at similar heart rates (tWT: 413±21, n=6; t3SA: 400±12, n=10; and t3SD: 420±12, n=10; in beats per minute) on mice of similar age of 3 to 4 months. A-C, At similar dP/dt max , cMyBP-C(t3SD) hearts had the greatest peak rate of pressure decrease dP/dt min , whereas cMyBP-C(t3SA) hearts had the slowest rate of pressure decrease. D, All hearts show similar dP/dt max . E, cMyBP-C(t3SD) hearts exhibited the largest values of dP/dt min , whereas cMyBP-C(t3SA) hearts exhibited the smallest values of dP/dt min . F, cMyBP-C(t3SD) hearts exhibited the greatest derivative pressure ratios, ie, dPR=(−dP/dt) min /(+dP/dt) max , whereas cMyBP-C(t3SA) hearts showed the smallest dPR. G, cMyBP-C(t3SD) hearts demonstrated the smallest (ie, fastest) pressure relaxation time constant τ-Glantz calculated by dP/dt=1/τ X (P offset -P[t]). H, Venous occlusion revealed that cMyBP-C(t3SA) hearts exhibited the greatest increase in diastolic pressure with increasing end-diastolic volume. I, cMyBP-C(t3SD) hearts demonstrated the smallest stiffness constant, whereas cMyBP-C(t3SA) hearts showed the largest stiffness constant. cMyBP indicates cardiac myosin-binding protein-C.
Thus, the differences in diastolic function cannot be explained on the basis of differences in systolic blood pressure.
In Situ Intracardiac Measurements Show That Myocardial Relaxation Rates Are Related to cMyBP-C Phosphorylation
Phosphomimetic cMyBP-C(t3SD) hearts showed the fastest rate of pressure decay (−dP/dt) min , whereas cMyBP-C(t3SA) hearts showed the slowest (−dP/dt) min ( Figure 4A-4C and  4E ). Because all mouse lines exhibited similar peak rates of pressure generation (+dP/dt) max , the enhanced relaxation in the cMyBP-C(t3SD) hearts cannot be explained as a simple consequence of faster cross-bridge cycling rate ( Figures 4A-4C and 4D) . The derivative pressure ratio (dPR)=(−dP/dt) min /(+dP/dt) max provides a means for comparing lusitropy because it indexes the heart's ability to relax to its maximum rate of pressure development. Comparison of dPRs ] i were measured simultaneously in intact papillary muscles from all mouse models as a function of increasing pacing frequency (1-2.5 Hz). A, cMyBP-C(tWT) papillary muscles exhibited acceleration of relaxation in response to increased pacing frequency, which is evident as an increase in the steepness of the peak rate of relaxation with respect to the maximum rate of force development, quantified as the derivative force ratio dFR=(−dF/dt) min /(+dF/dt) max . B, cMyBP-C(t3SA) papillary muscles exhibited a loss of frequency-dependent acceleration of relaxation (ie, dFR did not change with increasing pacing frequency). C, cMyBP-C(t3SD) muscles showed increased acceleration of relaxation (relative to cMyBP-C(tWT) muscles) in response to increased pacing frequency (ie, a greater dFR). D-F, Normalized [Ca 2+ ] i traces demonstrate that increasing pacing frequency shortened [Ca 2+ ] i decay times similarly in all mouse models. G, Increased pacing frequency causes acceleration of relaxation, evident as increased dFR in cMyBP-C(tWT) and cMyBP-C(t3SD), but not in cMyBP-C(t3SA) muscles. cMyBP-C(t3SD) muscles showed increased dFR in comparison with cMyBP-C(tWT), demonstrating enhanced relaxation. H, cMyBP-C(t3SD) papillary muscles showed greater force decay constant k force to indicate faster relaxation rates at higher pacing frequencies in comparison with cMyBP-C(t3SA) starting at 1.5 Hz and then cMyBP-C(tWT) starting at 2 Hz; k force was calculated as a single negative exponential from normalized force decay traces. I, Increasing pacing frequency caused similar increases in the [Ca 2+ ] i decay constant k Ca in all mouse models; k Ca was calculated as a single negative exponential from normalized [Ca 2+ ] i decay traces. yielded the following hierarchy: cMyBP-C(t3SD)>cMyBP-C(tWT)>cMyBP-C(t3SA); therefore, lusitropy as indicated by dPR is related to cMyBP-C phosphorylation status. Because (dP/dt) min and (dP/dt) max are related to E a and S a , respectively, these pressure measurements strongly confirm the echocardiographic findings. The τ-Glantz method was used to estimate the pressure decay time constant because this method uses change rates for calculation as a means to avoid equipment-related confounding pressure offset differences. 33 cMyBP-C(t3SD) hearts showed the smallest τ-Glantz, whereas cMyBP-C(t3SA) showed the largest τ-Glantz; therefore, comparison of time constants of pressure decay also showed that lusitropy is related to cMyBP-C phosphorylation status ( Figure 4G) . A diastolic pressure-volume stiffness constant was calculated to compare passive filling 26 among the mouse models studied. This analysis resulted in a hierarchy of stiffness constants: cMyBP-C(t3SD)<cMyBP-C(tWT)<cMyBP-C(t3SA). Thus, diastolic passive filling stiffness is inversely related to cMyBP-C phosphorylation status ( Figure 4H and 4I ). In summary, (−dP/dt) min , dPR, τ-Glantz, and stiffness constant all showed that the rate of myocardial relaxation increases with the level of cMyBP-C phosphorylation, whereas diastolic stiffness decreases with increasing phosphorylation.
Phosphomimetic cMyBP-C(t3SD) Papillary Muscles Exhibit Enhanced Relaxation Independent of [Ca 2+ ] i Decay Kinetics
cMyBP-C(tWT) and cMyBP-C(t3SD) papillary muscles exhibited frequency-dependent acceleration of relaxation that was absent in the phosphorylation-deficient cMyBP-C(t3SA) model. We used the derivative force ratio (dFR)=(−dF/dt) min / (+dF/dt) max 17 to assess the effect of increasing pacing frequency in all 3 mouse models. Increased pacing frequency accelerated relaxation, which is manifested as increasing dFR in cMyBP-C(tWT) (Figure 5A and 5G) and cMyBP-C(t3SD) ( Figure 5C and 5G) myocardium, but this was not the case in cMyBP-C(t3SA) muscle ( Figure 5B and 5G) . Moreover, cMyBP-C(t3SD) myocardium consistently exhibited greater dFRs than cMyBP-C(tWT), signifying enhanced relaxation ( Figure 5A, 5C, and 5G) .
cMyBP-C(t3SD) papillary muscles also showed faster rate of relaxation as evidenced by greater rate constant of force decay (k force ). cMyBP-C(t3SD) exhibited greater k force in comparison with cMyBP-C(t3SA) starting at 1.5 Hz. cMyBP-C(t3SD) exhibited greater k force in comparison with cMyBP-C(tWT) starting at 2 Hz (summary is given in Figure 5H Meanwhile, increased pacing frequency induced similar reductions in the [Ca 2+ ] i decay times in all 3 models, which translated to faster rate constants of [Ca 2+ ] i decay (k Ca ; Figure 5D -5F and 5H). Because all 3 mouse models showed similar increases in the k Ca with increased pacing frequency ( Figure 5I) , the different relaxation kinetics in the 3 mouse lines were not because of differences in the [Ca 2+ ] i decay kinetics. These results suggest that the enhanced lusitropy (eg, greater dFR and faster k force ) in the phosphomimetic cMyBP-C mouse is because of speeding of cross-bridge cycling kinetics, specifically cross-bridge detachment rates, and not alterations in the kinetics of the [Ca 2+ ] i transients.
Experiments on skinned myocardium in our previous study yielded similar tension-pCa relationships in cMyBP-C(tWT) and cMyBP-C(t3SA) myocardium. 14 Skinned myocardium studies in this work also showed that cMyBP-C(tWT) and cMyBP-C(t3SD) have similar tension-pCa relationships ( Figure VI in the Data Supplement). Consequently, differences in relaxation kinetics cannot be explained by differences in calcium sensitivity.
CaMK2δ and PKA can phosphorylate cMyBP-C and calcium-handling proteins. Thus, expression and phosphorylation status of these kinases were examined by Western blotting. Expression and phosphorylation levels of these kinases seem to be similar across all the mouse lines, which suggest that kinase activities do not differ between lines ( Figure V in the Data Supplement). Thus, differences in cardiac function cannot be attributed to differences in CaMK2δ or PKA activity.
All Mouse Models Showed Similarly Negligible Levels of Fibrosis
A study was performed to determine whether differences in tissue fibrosis contributed to the observed differences in diastolic function in the 3 mouse lines. The study involved semiautomated image analyses using ImageJ software on trichrome-stained heart sections. Each heart was examined in 3 full sections that were further subdivided into 48 to 68 regions, including the apex, LV free wall, interventricular septum, and right ventricle free wall. All mouse lines exhibited <0.2% fibrosis (tWT, 0.096±0.041%; t3SA, 0.037±0.018%; and t3SD, 0.028±0.005; n=3 hearts for all lines, mice of 6 weeks of age). There were no statistical differences between the mouse lines. Thus, there are no significant increases or differences in the amount of fibrosis in any of the mouse lines that would explain the differences in diastolic function. Additional methods and results are available in Figure VIII 
Discussion
This study was undertaken to determine the contribution of cMyBP-C phosphorylation to cardiac diastolic function, which was done by comparing cardiac function in mouse models expressing phosphorylation-deficient cMyBP-C(t3SA), phosphomimetic cMyBP-C(t3SD), or normally phosophorylatable cMyBP-C(tWT). The key findings in echocardiography and intracardiac pressure/volume measurements demonstrate that diastolic function varies widely with the phosphorylation state of cMyBP-C; therefore, cMyBP-C is a key determinant of myocardial relaxation. Phosphorylation mimetic cMyBP-C(t3SD) hearts consistently showed enhanced relaxation and enhanced diastolic function. At the opposite extreme, phosphorylation-deficient cMyBP-C(t3SA) hearts consistently showed impaired relaxation and diastolic dysfunction. Furthermore, cMyBP-C(t3SA) mice showed phenotypes that resemble human HFpEF. Simultaneous force and [Ca 2+ ] i measurements were done on intact papillary muscles to elucidate the underlying mechanism. The results suggest that cMyBP-C phosphorylation increased the rates of cross-bridge detachment to mediate enhancement of diastolic function (Table) .
Enhancement of Myocardial Relaxation Because of cMyBP-C Phosphorylation Is Likely due to a Faster Rate Of Cross-Bridge Detachment
The relaxation rates measured in papillary muscles increased with cMyBP-C phosphorylation, in the following rank order of force decay rate constants k force [cMyBP-C(t3SD)>cMyBP-C(tWT)>cMyBP-C(t3SA)]. cMyBP-C(t3SD) and cMyBP-C(tWT) papillary muscles exhibited frequency-dependent acceleration of relaxation as evidenced by increasing dFR as pacing frequency was increased. The underlying greater increases in |(−dF/dt) min | relative to |(+dF/dt) max | suggest that an increased rate of cross-bridge detachment underlies the acceleration of relaxation. All 3 mouse models exhibited similar [Ca 2+ ] i decay rate constants, k Ca , at 1 Hz and similar frequency-dependent increases in k Ca , ie, increased pacing frequency similarly accelerated calcium reuptake in all models. Consequently, the faster relaxation kinetics (k force ) and acceleration of relaxation (dFR) with increasing pacing frequency observed with increasing cMyBP-C phosphorylation cannot be attributed to changes in calcium-handling kinetics. Present and previous 14 experiments on skinned myocardium also yielded similar calcium sensitivities of force among all 3 mouse models. The absence of differences in calcium handling or calcium sensitivity further supports the conclusion that cMyBP-C phosphorylation causes faster cross-bridge detachment rates. Another study demonstrating that phosphorylation of cMyBP-C increased the crossbridge detachment rate without affecting the attachment rate is consistent with such a mechanism. 16 Likewise, the findings that dephosphorylated cMyBP-C slowed actin-sliding velocity compared with native thick filaments 34 and phosphorylated cMyBP-C modified the torsional flexibility of actin 35 are consistent with the idea that cross-bridge detachment rates are accelerated by phosphorylation of cMyBP-C. Furthermore, the cMyBP-C(−/−) 18 mouse exhibits faster cross-bridge cycling rates 14 and an inability to accelerate relaxation in response to increased pacing frequency, thereby resulting in diastolic dysfunction. 17 In this scenario, there is no cMyBP-C presence to modulate cross-bridge detachment rates to accelerate relaxation. A possible explanation for the effect of cMyBP-C phosphorylation to increase the cross-bridge detachment rate is that product release steps in the cross-bridge cycle are accelerated because of reduced binding of phosphorylated cMyBP-C to the myosin heavy chain, 36 thereby promoting detachment.
cMyBP-C Phosphorylation Modulates Cardiac Diastolic Function
Measurements of cardiac function in a range of animal models corroborate the idea that cMyBP-C phosphorylation levels modulate diastolic function. For example, a hypertensive mouse model exhibited both diastolic dysfunction and decreased cMyBP-C phosphorylation at Ser282. 37 A review 17 has summarized that essentially, all genetically modified mouse models of cMyBP-C dephosphorylation exhibit some form of diastolic dysfunction. On the other hand, increased cMyBP-C phosphorylation at Ser273/ Ser282 was associated with preserved diastolic function despite increased blood pressure, increased peak intracellular calcium, and decreased cTnI phosphorylation in an angiotensin-II infusion rat model of hypertension. 38 Older hypertensive dogs with HFpEF exhibited diastolic dysfunction in the presence of hypophosphorylation of cMyBP-C along with other contractile proteins. 39 This work clarifies the roles of cMyBP-C phosphorylation in changes of diastolic function found in previous studies by demonstrating that cMyBP-C phosphorylation can directly modulate diastolic function in the absence of aging, hypertension, or volume overload. Existing data from humans show that hypophosphorylation of cMyBP-C is associated with diastolic dysfunction. Patients exhibiting a combination of hypertension, LV hypertrophy, normal ejection fraction, and diastolic dysfunction were found to have decreased cMyBP-C phosphorylation. 40 Diastolic dysfunction with normal ejection fraction is a prominent aspect of hypertrophic cardiomyopathy. Samples of myocardium obtained during myectomy surgery to relieve outflow obstruction in patients with hypertrophic cardiomyopathy exhibited decreased cMyBP-C phosphorylation, 41, 42 suggesting that hypophosphorylation of cMyBP-C is involved in the pathogenesis of diastolic dysfunction in these patients. Thus, these clinical data support the notion that cMyBP-C phosphorylation modulate diastolic function.
Cardiac phenotypes in the cMyBP-C(t3SA) mouse resemble human HFpEF. Decreased daily running distances, increased lung/body weight ratio (ie, pulmonary edema), and increased BNP mRNA levels combine to suggest the presence of HF in cMyBP-C(t3SA) mice. Furthermore, 12-month-old cMyBP-C(t3SA) hearts show similar LV internal diameter during diastole, similar LVEF, and diastolic dysfunction in comparison with cMyBP-C(tWT) mice. Human HFpEF is defined by the presence of HF with EF typically >50%, 43 with diastolic dysfunction as a major contributing factor. 3 A majority of patients with HFpEF exhibit hypertrophy. 44 Thus, the combination of preserved EF, diastolic dysfunction, and hypertrophy in the presence of HF suggests that the cMyBP-C(t3SA) mouse approximates human HFpEF. On the other hand, cMyBP-C(t3SD) hearts exhibiting enhanced diastolic function that persists into older age suggest that phosphorylation of cMyBP-C may be a target for treating HFpEF.
Observed Changes Are Not Attributable To Differences in Post-Translational Modifications of Other Regulatory Contractile Proteins, Selected Kinases, or Fibrosis
Similar distributions of 2D-DIGE spots for cTnI, cardiac troponin-T4, cardiac tropomyosin, and myosin light chain-2 showed that there are no differences in post-translational modifications of these proteins in our mutant mouse lines. Phosphorylation staining also showed similar levels of titin phosphorylation. Expression and phosphorylation levels of CaMK2δ and PKA are similar. All mouse lines also demonstrated similarly negligible fibrosis. Therefore, differences in cardiac function cannot be attributed to differences in posttranslational modification of myofilament proteins (cTnI, cardiac troponin-T4, cardiac tropomyosin, and myosin light chain-2), titin phosphorylation, CaMK2δ, PKA, or fibrosis.
Potential Limitations
At present, ≈17 potential phosphorylation sites, including serines, tyrosines, and threonines, 45 have been identified in cMyBP-C. Our mouse models only address 3 serine phosphorylation sites. Thus, the roles of the remaining phosphorylation sites remain to be determined. Despite carefully excluding many possible confounding differences (eg, calcium transients, phosphorylation of other contractile proteins, fibrosis), undetected compensation in response to our genetic manipulations may still have taken place to contribute to the observed differences.
β-adrenergic receptor activation leading to PKA phosphorylation of cMyBP-C can also activate G-protein receptor kinase-2 signaling pathway. 46 This parallel G-protein receptor kinase-2 signaling pathway can depress cardiac function and cause deleterious remodeling. 47 Angiotensin-II causing reactive oxygen radicals to constitutively activate CaMK2δ is another parallel signaling pathway to cMyBP-C phosphorylation that can cause harm. 48 Thus, challenges in developing therapies would be finding methods to phosphorylate cMyBP-C or maintain cMyBP-C phosphorylation independently of these parallel signaling pathways.
Conclusions
Echocardiography and pressure/volume measurements show that cMyBP-C phosphorylation enhances relaxation, whereas the absence of cMyBP-C phosphorylation at the PKA sites in the M-domain causes diastolic dysfunction. Simultaneous force and [Ca 2+ ] i measurements in intact papillary muscles suggest that cMyBP-C phosphorylation increases the rates of cross-bridge detachment relative to attachment as the underlying mechanism for enhanced relaxation. The absence of cMyBP-C phosphorylation at the M-domain sites results in phenotypes resembling HFpEF. Thus, interventions designed to mimic or increase the levels of cMyBP-C phosphorylation can be potential treatments for HFpEF.
